C26H44O9
Neat
500.64
Mupirocin EP Impurity E; 71087-96-2; W3F3R97750; 9-(((2E)-4-((2R, 3RS, 4aS, 7S, 8S, 8aR)-3, 8-Dihydroxy-2-((1S, 2S)-2-hydroxy-1-methylpropyl)hexahydro-2H, 5H-pyrano(4, 3-b)pyran-7-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid; Nonanoic acid, 9-(((2E)-4-((2R, 3S, 4aS, 7S, 8S, 8aR)-hexahydro-3, 8-dihydroxy-2-((1S, 2S)-2-hydroxy-1-methylpropyl)-2H, 5H-pyrano(4, 3-b)pyran-7-yl)-3-methyl-1-oxo-2-buten-1-yl)oxy)-; UNII-W3F3R97750; Mupirocin calcium impurity E [EP]; IP27268; MUPIROCIN IMPURITY E [EP IMPURITY]; G87736; MUPIROCIN CALCIUM IMPURITY E [EP IMPURITY]; Q27292253; [2R-[2a(1S*, 2S*), 3b, 4a-a, 7b(E), 8a, 8a-b]]-9-[[4-[Hexahydro-3, 8-dihydroxy-2-(2-hydroxy-1-methylpropyl)-2H, 5H-pyrano[4, 3-b]pyran-7-yl]- 3-methyl-1-oxo-2-butenyl]oxy]nonanoic acid monosodium salt; 9-(((E)-4-((2R, 4aS, 7S, 8S, 8aR)-3, 8-dihydroxy-2-((2S, 3S)-3-hydroxybutan-2-yl)octahydropyrano[4, 3-b]pyran-7-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid; 9-[(E)-4-[(2R, 4aS, 7S, 8S, 8aR)-3, 8-dihydroxy-2-[(1S, 2S)-2-hydroxy-1-methyl-propyl]-2, 3, 4, 4a, 5, 7, 8, 8a-octahydropyrano[3 and 2-c]pyran-7-yl]-3-methyl-but-2-enoyl]oxynonanoic acid
9-[(E)-4-[(2R, 4aS, 7S, 8S, 8aR)-3, 8-dihydroxy-2-[(2S, 3S)-3-hydroxybutan-2-yl]-2, 3, 4, 4a, 5, 7, 8, 8a-octahydropyrano[3 and 2-c]pyran-7-yl]-3-methylbut-2-enoyl]oxynonanoic acid
InChI=1S/C26H44O9/c1-16(13-23(31)33-11-9-7-5-4-6-8-10-22(29)30)12-21-24(32)26-19(15-34-21)14-20(28)25(35-26)17(2)18(3)27/h13,17-21,24-28,32H,4-12,14-15H2,1-3H3,(H,29,30)/b16-13+/t17-,18-,19-,20?,21-,24-,25+,26+/m0/s1